외상성 뇌손상(TBI) 환자수 분석 및 예측(2026-2035년)

Traumatic brain injury is one of the leading causes of death and disability worldwide and affects individuals across all age groups. Although improvements in trauma care have reduced mortality in many countries, increasing survival has resulted in a growing population requiring long-term rehabilitation and neurological management. Patient population analysis provides valuable insights into diagnosed prevalence, incidence, age and gender distribution, injury severity, healthcare utilization, regional disease burden, and future patient population forecasts that support healthcare planning, pharmaceutical development, and commercial strategy.

Market Drivers

Rising Incidence of Traumatic Brain Injury

Increasing motor vehicle accidents, falls among elderly individuals, sports-related concussions, occupational injuries, and military trauma continue to drive growth in the global TBI patient population. Population growth and aging have increased the absolute number of patients despite declining age-standardized rates.

Improved Diagnosis and Reporting

Greater awareness, wider availability of CT and MRI imaging, standardized trauma protocols, and expanded neurotrauma registries have improved diagnosis and reporting of traumatic brain injuries, increasing the identified patient population.

Growing Survival Rates

Advances in emergency medicine, neurosurgery, intensive care, and rehabilitation have improved survival among patients with moderate and severe traumatic brain injury, increasing the number of individuals living with long-term neurological impairment.

Expansion of Epidemiological Research

Governments, healthcare organizations, and research institutions continue investing in national trauma registries, real-world evidence generation, and epidemiological studies that provide more accurate estimates of disease burden and patient populations.

Market Restraints

Underdiagnosis of Mild TBI

Many patients with mild traumatic brain injury or concussion do not seek medical attention or remain undiagnosed, resulting in underestimation of the true patient population.

Regional Differences in Healthcare Access

Limited access to diagnostic imaging, trauma centers, and neurological specialists in low- and middle-income countries contributes to incomplete disease reporting and delayed diagnosis.

Variability in Data Collection

Differences in healthcare infrastructure, trauma registries, diagnostic criteria, and reporting practices create variation in epidemiological estimates across countries and regions.

Patient Population Insights

The global traumatic brain injury patient population can be segmented by injury severity, age group, gender, cause of injury, care setting, and geography.

By injury severity, the patient population includes mild traumatic brain injury, moderate traumatic brain injury, and severe traumatic brain injury. Mild traumatic brain injury accounts for the majority of diagnosed cases, while moderate and severe injuries contribute disproportionately to mortality, hospitalization, and long-term disability.

By age group, the patient population includes pediatric, adolescent, adult, and geriatric patients. Older adults experience increasing incidence because of falls, while adolescents and young adults are commonly affected by road traffic accidents, sports injuries, and occupational trauma.

By gender, traumatic brain injury occurs more frequently in males than females across most age groups because of greater exposure to occupational hazards, contact sports, military service, and road traffic accidents.

By cause of injury, the patient population includes cases resulting from falls, road traffic accidents, sports injuries, workplace injuries, assaults, blast injuries, and other causes. Falls remain the leading cause globally, followed by road injuries.

By care setting, patients receive treatment through emergency departments, trauma centers, hospitals, intensive care units, rehabilitation centers, and outpatient neurological clinics, depending on injury severity and long-term recovery needs.

Patient Population Trends

The global traumatic brain injury patient population continues to evolve because of demographic and healthcare changes.

Key trends include:

• Increasing absolute number of traumatic brain injury cases worldwide.
• Growing prevalence among aging populations because of falls.
• Rising recognition of sports-related concussion.
• Improved survival leading to larger rehabilitation populations.
• Expansion of national trauma registries and real-world databases.
• Greater use of digital health and artificial intelligence for patient monitoring.
• Increasing focus on long-term neurological outcomes and quality of life.

Regional Insights

North America remains one of the largest traumatic brain injury patient populations because of comprehensive trauma reporting systems, advanced emergency care, and widespread diagnostic capabilities. Improved survival has increased the number of patients requiring rehabilitation and long-term neurological care.

Europe maintains extensive epidemiological surveillance supported by established trauma registries and coordinated healthcare systems. Falls among elderly individuals remain a major contributor to the regional disease burden.

Asia-Pacific accounts for the largest absolute patient population because of its large population base, increasing urbanization, expanding transportation networks, and growing incidence of road traffic injuries. China and India contribute significantly to global TBI case numbers.

Latin America and the Middle East & Africa continue to experience increasing traumatic brain injury incidence owing to expanding urban populations, road traffic injuries, occupational accidents, and improving access to trauma care.

Competitive Landscape

The traumatic brain injury patient population analysis market involves pharmaceutical companies, biotechnology firms, academic institutions, epidemiology research organizations, healthcare providers, government agencies, and contract research organizations.

Organizations continue investing in epidemiological modeling, patient registries, real-world evidence generation, healthcare databases, and artificial intelligence-based population analytics. Strategic collaborations between research institutions, healthcare systems, and industry participants continue to improve understanding of disease burden and support future therapeutic development.

Future Outlook

The future of traumatic brain injury patient population analysis will be driven by improvements in digital health, artificial intelligence, electronic health records, trauma registries, and precision epidemiology. Better diagnostic technologies, standardized reporting systems, and broader international collaboration are expected to improve patient identification and disease surveillance.

Growing investment in neurological research, rehabilitation services, and long-term patient monitoring will strengthen epidemiological forecasting while supporting healthcare planning, clinical trial recruitment, commercial strategy, and public health initiatives through 2035.

Conclusion

The Global Traumatic Brain Injury Patient Population Analysis highlights the substantial and growing worldwide burden of traumatic brain injury. Although age-standardized incidence has declined in many regions, population growth, aging, and improved survival continue to increase the overall number of patients living with traumatic brain injury. Comprehensive patient population analysis remains essential for healthcare planning, pharmaceutical development, clinical research, rehabilitation planning, and long-term commercial decision-making.

Key Benefits of this Report

• Comprehensive analysis of global traumatic brain injury patient populations and disease burden.
• Detailed assessment of incidence, prevalence, demographic distribution, and injury severity.
• Insights into regional epidemiological trends and long-term patient forecasts.
• Evaluation of healthcare utilization, unmet medical needs, and future treatment opportunities.
• Valuable resource for pharmaceutical companies, biotechnology firms, healthcare providers, researchers, investors, consultants, and policymakers.

What Businesses Use Our Reports For

Patient population forecasting, epidemiology assessment, clinical trial planning, commercial opportunity analysis, healthcare resource planning, market access strategy, competitive intelligence, investment evaluation, and long-term strategic decision-making.

Report Coverage

• Historical patient population data from 2021 to 2025, Base Year 2025, and Forecast Period 2026 to 2035
• Comprehensive analysis of traumatic brain injury patient populations by injury severity, age group, gender, cause of injury, care setting, and geography
• Evaluation of incidence, prevalence, diagnosed patient population, mortality, long-term disability, and epidemiological trends
• Assessment of demographic characteristics, regional disease burden, healthcare utilization, and unmet medical needs
• Analysis of patient population forecasts, epidemiological modeling, and future disease burden across major global markets through 2035.

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Report Scope and Objectives
• 1.2 Key Findings
• 1.3 Patient Population Overview
• 1.4 Epidemiology Highlights
• 1.5 Disease Burden Insights
• 1.6 Key Growth Trends
• 1.7 Strategic Insights
• 1.8 Future Outlook

2. Disease Overview

• 2.1 Introduction to Traumatic Brain Injury (TBI)
• 2.2 Disease Definition and Classification
  • 2.2.1 Mild Traumatic Brain Injury (Concussion)
  • 2.2.2 Moderate Traumatic Brain Injury
  • 2.2.3 Severe Traumatic Brain Injury
• 2.3 Etiology and Risk Factors
• 2.4 Pathophysiology Overview
• 2.5 Clinical Manifestations
• 2.6 Diagnostic Pathway
• 2.7 Disease Progression and Outcomes
• 2.8 Complications and Long-Term Consequences
• 2.9 Unmet Clinical Needs

3. Research Methodology and Epidemiology Framework

• 3.1 Epidemiology Methodology
• 3.2 Data Collection Framework
• 3.3 Patient Population Modeling Approach
• 3.4 Forecasting Methodology (2025-2045)
• 3.5 Assumptions and Limitations
• 3.6 Data Validation and Triangulation

4. Global Traumatic Brain Injury Patient Population Overview

• 4.1 Total Incident Cases
• 4.2 Total Prevalent Cases
• 4.3 Diagnosed Cases
• 4.4 Treated Cases
• 4.5 Severity-Specific Patient Population
• 4.6 Age-Specific Patient Population
• 4.7 Gender-Specific Patient Population
• 4.8 Mortality Analysis
• 4.9 Forecast Analysis (2025-2045)

5. Patient Population Segmentation by Injury Severity

• 5.1 Mild Traumatic Brain Injury
  • 5.1.1 Incident Cases
  • 5.1.2 Prevalent Cases
  • 5.1.3 Diagnosed Cases
  • 5.1.4 Treated Cases
  • 5.1.5 Forecast Analysis
• 5.2 Moderate Traumatic Brain Injury
  • 5.2.1 Incident Cases
  • 5.2.2 Prevalent Cases
  • 5.2.3 Diagnosed Cases
  • 5.2.4 Treated Cases
  • 5.2.5 Forecast Analysis
• 5.3 Severe Traumatic Brain Injury
  • 5.3.1 Incident Cases
  • 5.3.2 Prevalent Cases
  • 5.3.3 Diagnosed Cases
  • 5.3.4 Treated Cases
  • 5.3.5 Forecast Analysis

6. Patient Population Segmentation by Cause of Injury

• 6.1 Falls
  • 6.1.1 Incident Cases
  • 6.1.2 Prevalent Cases
  • 6.1.3 Forecast Analysis
• 6.2 Road Traffic Accidents
  • 6.2.1 Incident Cases
  • 6.2.2 Prevalent Cases
  • 6.2.3 Forecast Analysis
• 6.3 Sports and Recreational Injuries
  • 6.3.1 Incident Cases
  • 6.3.2 Prevalent Cases
  • 6.3.3 Forecast Analysis
• 6.4 Occupational Injuries
  • 6.4.1 Incident Cases
  • 6.4.2 Prevalent Cases
  • 6.4.3 Forecast Analysis
• 6.5 Assault and Violence-Related Injuries
  • 6.5.1 Incident Cases
  • 6.5.2 Prevalent Cases
  • 6.5.3 Forecast Analysis
• 6.6 Military and Blast-Related Injuries
  • 6.6.1 Incident Cases
  • 6.6.2 Prevalent Cases
  • 6.6.3 Forecast Analysis

7. Patient Population Segmentation by Age Group

• 7.1 Pediatric Population (0-17 Years)
  • 7.1.1 Incident Cases
  • 7.1.2 Prevalent Cases
  • 7.1.3 Diagnosed Cases
  • 7.1.4 Forecast Analysis
• 7.2 Adult Population (18-64 Years)
  • 7.2.1 Incident Cases
  • 7.2.2 Prevalent Cases
  • 7.2.3 Diagnosed Cases
  • 7.2.4 Forecast Analysis
• 7.3 Geriatric Population (65 Years and Above)
  • 7.3.1 Incident Cases
  • 7.3.2 Prevalent Cases
  • 7.3.3 Diagnosed Cases
  • 7.3.4 Forecast Analysis

8. Patient Population Segmentation by Gender

• 8.1 Male Population
  • 8.1.1 Incident Cases
  • 8.1.2 Prevalent Cases
  • 8.1.3 Diagnosed Cases
  • 8.1.4 Forecast Analysis
• 8.2 Female Population
  • 8.2.1 Incident Cases
  • 8.2.2 Prevalent Cases
  • 8.2.3 Diagnosed Cases
  • 8.2.4 Forecast Analysis

9. Disease Burden and Healthcare Utilization Analysis

• 9.1 Emergency Department Visits
• 9.2 Hospitalized Cases
• 9.3 Intensive Care Unit Admissions
• 9.4 Rehabilitation Utilization
• 9.5 Long-Term Disability Burden
• 9.6 Mortality Burden
• 9.7 Economic Burden Assessment
• 9.8 Quality of Life Impact Analysis
• 9.9 Future Disease Burden Outlook

10. Geographical Analysis

• 10.1 North America
  • 10.1.1 Total Prevalence
  • 10.1.2 Total Incidence
  • 10.1.3 Diagnosed Cases
  • 10.1.4 Severity Distribution
  • 10.1.5 Age-Specific Epidemiology
  • 10.1.6 Gender-Specific Epidemiology
  • 10.1.7 Forecast Analysis
• 10.2 Europe
  • 10.2.1 Total Prevalence
  • 10.2.2 Total Incidence
  • 10.2.3 Diagnosed Cases
  • 10.2.4 Severity Distribution
  • 10.2.5 Age-Specific Epidemiology
  • 10.2.6 Gender-Specific Epidemiology
  • 10.2.7 Forecast Analysis
• 10.3 Asia-Pacific
  • 10.3.1 Total Prevalence
  • 10.3.2 Total Incidence
  • 10.3.3 Diagnosed Cases
  • 10.3.4 Severity Distribution
  • 10.3.5 Age-Specific Epidemiology
  • 10.3.6 Gender-Specific Epidemiology
  • 10.3.7 Forecast Analysis
• 10.4 Latin America
  • 10.4.1 Total Prevalence
  • 10.4.2 Total Incidence
  • 10.4.3 Diagnosed Cases
  • 10.4.4 Severity Distribution
  • 10.4.5 Age-Specific Epidemiology
  • 10.4.6 Gender-Specific Epidemiology
  • 10.4.7 Forecast Analysis
• 10.5 Middle East & Africa
  • 10.5.1 Total Prevalence
  • 10.5.2 Total Incidence
  • 10.5.3 Diagnosed Cases
  • 10.5.4 Severity Distribution
  • 10.5.5 Age-Specific Epidemiology
  • 10.5.6 Gender-Specific Epidemiology
  • 10.5.7 Forecast Analysis

11. Key Countries Analysis

• 11.1 United States
  • 11.1.1 Total Prevalence
  • 11.1.2 Total Incidence
  • 11.1.3 Diagnosed Cases
  • 11.1.4 Severity Distribution
  • 11.1.5 Age-Specific Epidemiology
  • 11.1.6 Gender-Specific Epidemiology
  • 11.1.7 Forecast Analysis
• 11.2 Canada
  • 11.2.1 Total Prevalence
  • 11.2.2 Total Incidence
  • 11.2.3 Diagnosed Cases
  • 11.2.4 Severity Distribution
  • 11.2.5 Age-Specific Epidemiology
  • 11.2.6 Gender-Specific Epidemiology
  • 11.2.7 Forecast Analysis
• 11.3 Germany
  • 11.3.1 Total Prevalence
  • 11.3.2 Total Incidence
  • 11.3.3 Diagnosed Cases
  • 11.3.4 Severity Distribution
  • 11.3.5 Age-Specific Epidemiology
  • 11.3.6 Gender-Specific Epidemiology
  • 11.3.7 Forecast Analysis
• 11.4 United Kingdom
  • 11.4.1 Total Prevalence
  • 11.4.2 Total Incidence
  • 11.4.3 Diagnosed Cases
  • 11.4.4 Severity Distribution
  • 11.4.5 Age-Specific Epidemiology
  • 11.4.6 Gender-Specific Epidemiology
  • 11.4.7 Forecast Analysis
• 11.5 France
  • 11.5.1 Total Prevalence
  • 11.5.2 Total Incidence
  • 11.5.3 Diagnosed Cases
  • 11.5.4 Severity Distribution
  • 11.5.5 Age-Specific Epidemiology
  • 11.5.6 Gender-Specific Epidemiology
  • 11.5.7 Forecast Analysis
• 11.6 Italy
  • 11.6.1 Total Prevalence
  • 11.6.2 Total Incidence
  • 11.6.3 Diagnosed Cases
  • 11.6.4 Severity Distribution
  • 11.6.5 Age-Specific Epidemiology
  • 11.6.6 Gender-Specific Epidemiology
  • 11.6.7 Forecast Analysis
• 11.7 Spain
  • 11.7.1 Total Prevalence
  • 11.7.2 Total Incidence
  • 11.7.3 Diagnosed Cases
  • 11.7.4 Severity Distribution
  • 11.7.5 Age-Specific Epidemiology
  • 11.7.6 Gender-Specific Epidemiology
  • 11.7.7 Forecast Analysis
• 11.8 China
  • 11.8.1 Total Prevalence
  • 11.8.2 Total Incidence
  • 11.8.3 Diagnosed Cases
  • 11.8.4 Severity Distribution
  • 11.8.5 Age-Specific Epidemiology
  • 11.8.6 Gender-Specific Epidemiology
  • 11.8.7 Forecast Analysis
• 11.9 Japan
  • 11.9.1 Total Prevalence
  • 11.9.2 Total Incidence
  • 11.9.3 Diagnosed Cases
  • 11.9.4 Severity Distribution
  • 11.9.5 Age-Specific Epidemiology
  • 11.9.6 Gender-Specific Epidemiology
  • 11.9.7 Forecast Analysis
• 11.10 India
  • 11.10.1 Total Prevalence
  • 11.10.2 Total Incidence
  • 11.10.3 Diagnosed Cases
  • 11.10.4 Severity Distribution
  • 11.10.5 Age-Specific Epidemiology
  • 11.10.6 Gender-Specific Epidemiology
  • 11.10.7 Forecast Analysis
• 11.11 South Korea
  • 11.11.1 Total Prevalence
  • 11.11.2 Total Incidence
  • 11.11.3 Diagnosed Cases
  • 11.11.4 Severity Distribution
  • 11.11.5 Age-Specific Epidemiology
  • 11.11.6 Gender-Specific Epidemiology
  • 11.11.7 Forecast Analysis
• 11.12 Australia
  • 11.12.1 Total Prevalence
  • 11.12.2 Total Incidence
  • 11.12.3 Diagnosed Cases
  • 11.12.4 Severity Distribution
  • 11.12.5 Age-Specific Epidemiology
  • 11.12.6 Gender-Specific Epidemiology
  • 11.12.7 Forecast Analysis

12. Epidemiology and Patient Population Forecasts (2025-2045)

• 12.1 Global Patient Population Forecast
• 12.2 Regional Patient Population Forecast
• 12.3 Severity-Specific Forecast
• 12.4 Age-Specific Forecast
• 12.5 Gender-Specific Forecast
• 12.6 Diagnosed Patient Forecast
• 12.7 Treated Patient Forecast
• 12.8 Disease Burden Forecast
• 12.9 Key Epidemiological Trends

13. Company Profiles

• 13.1 Abbott Laboratories
  • 13.1.1 Overview
  • 13.1.2 Financials
  • 13.1.3 TBI Diagnostic Portfolio Overview
  • 13.1.4 Epidemiology and Screening Initiatives
  • 13.1.5 Biomarker Testing Programs
  • 13.1.6 Research Collaborations
  • 13.1.7 Strategic Initiatives
  • 13.1.8 Recent Developments
• 13.2 BioMerieux SA
  • 13.2.1 Overview
  • 13.2.2 Financials
  • 13.2.3 TBI Diagnostic Portfolio Overview
  • 13.2.4 Biomarker Research Programs
  • 13.2.5 Epidemiology Support Initiatives
  • 13.2.6 Research Collaborations
  • 13.2.7 Strategic Initiatives
  • 13.2.8 Recent Developments
• 13.3 Oragenics, Inc
  • 13.3.1 Overview
  • 13.3.2 Financials
  • 13.3.3 TBI Diagnostic Portfolio Overview
  • 13.3.4 Biomarker Development Programs
  • 13.3.5 Screening and Detection Initiatives
  • 13.3.6 Research Collaborations
  • 13.3.7 Strategic Initiatives
  • 13.3.8 Recent Developments
• 13.4 Quanterix Corporation
  • 13.4.1 Overview
  • 13.4.2 Financials
  • 13.4.3 TBI Diagnostic Portfolio Overview
  • 13.4.4 Biomarker Development Programs
  • 13.4.5 Epidemiology Research Support
  • 13.4.6 Research Collaborations
  • 13.4.7 Strategic Initiatives
  • 13.4.8 Recent Developments
• 13.5 Roche Holding AG
  • 13.5.1 Overview
  • 13.5.2 Financials
  • 13.5.3 TBI Diagnostic Portfolio Overview
  • 13.5.4 Biomarker Development Programs
  • 13.5.5 Epidemiology Research Support
  • 13.5.6 Research Collaborations
  • 13.5.7 Strategic Initiatives
  • 13.5.8 Recent Developments
• 13.6 Siemens Healthineers
  • 13.6.1 Overview
  • 13.6.2 Financials
  • 13.6.3 TBI Diagnostic Portfolio Overview
  • 13.6.4 Biomarker Testing Programs
  • 13.6.5 Epidemiology Research Support
  • 13.6.6 Research Collaborations
  • 13.6.7 Strategic Initiatives
  • 13.6.8 Recent Developments
• 13.7 Beckman Coulter
  • 13.7.1 Overview
  • 13.7.2 Financials
  • 13.7.3 TBI Diagnostic Portfolio Overview
  • 13.7.4 Biomarker Research Programs
  • 13.7.5 Epidemiology Research Support
  • 13.7.6 Research Collaborations
  • 13.7.7 Strategic Initiatives
  • 13.7.8 Recent Developments
• 13.8 Fujirebio
  • 13.8.1 Overview
  • 13.8.2 Financials
  • 13.8.3 TBI Diagnostic Portfolio Overview
  • 13.8.4 Neurology Biomarker Programs
  • 13.8.5 Epidemiology Research Support
  • 13.8.6 Research Collaborations
  • 13.8.7 Strategic Initiatives
  • 13.8.8 Recent Developments
• 13.9 Hope Biosciences
  • 13.9.1 Overview
  • 13.9.2 Financials
  • 13.9.3 TBI Diagnostic Portfolio Overview
  • 13.9.4 Biomarker Development Programs
  • 13.9.5 Epidemiology Research Support
  • 13.9.6 Research Collaborations
  • 13.9.7 Strategic Initiatives
  • 13.9.8 Recent Developments
• 13.10 Sysmex Corporation
  • 13.10.1 Overview
  • 13.10.2 Financials
  • 13.10.3 TBI Diagnostic Portfolio Overview
  • 13.10.4 Biomarker Research Programs
  • 13.10.5 Epidemiology Research Support
  • 13.10.6 Research Collaborations
  • 13.10.7 Strategic Initiatives
  • 13.10.8 Recent Developments

14. Key Opinion Leader (KOL) Insights

• 14.1 Epidemiology Trends
• 14.2 Disease Burden Assessment
• 14.3 Diagnostic Challenges
• 14.4 Future Patient Population Trends
• 14.5 Expert Outlook

15. Research Methodology

• 15.1 Primary Research
• 15.2 Secondary Research
• 15.3 Epidemiology Modeling Methodology
• 15.4 Forecasting Methodology
• 15.5 Data Validation and Triangulation
• 15.6 Assumptions and Limitations

16. Appendix

• 16.1 Abbreviations
• 16.2 Glossary of Terms
• 16.3 References
• 16.4 List of Tables
• 16.5 List of Figures
• 16.6 Epidemiology Data Sources
• 16.7 Public Health Sources
• 16.8 Company Sources
• 16.9 Scientific Literature Sources